As momentum builds anew towards ISO IDMP compliance, life sciences companies could be forgiven for a lacklustre response, after a series of delays. Most organisations have already jumped through so many regulatory hoops to meet each new set of guidelines. Frits Stulp at Iperion Life Sciences Consultancy examines how there is another far more important factor at play here, and that is the public’s growing appetite for access to medicinal product data.